Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis ...

Q1 2026 Management View CEO Jennifer Good said, "2026 is an important year of execution for the company," and tied the quarter’s focus to multiple trial starts across IPF-related chronic cough, ...

Q1 2026 Management View Dr. Martine Rothblatt framed the quarter around two Phase III programs, saying, "We just proved beyond a shadow of a doubt with a p-value of less than 0.0001 that we have 2 ...

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA ...

IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...

Anxiety and depression are prevalent in patients with IPF and are linked to increased breathlessness and lower energy levels.

Cellular senescence contributes to IPF progression by promoting inflammation and disrupting immune homeostasis. Four key genes—CDKN2A, VEGFA, SOX2, and FOXO3—were identified as differentially ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prior to this trial, CS014 had positive outcomes in an ...

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This article is more than 6 years old. Idiopathic pulmonary ...